{"filings":[{"id":122705,"accession_number":"0001171843-25-007836","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"XBiotech CEO John Simard retires; CSO Sushma Shivaswamy named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Simard retired as CEO/President effective Dec 8, 2025; continues as Chairman.","Sushma Shivaswamy, 47, appointed interim CEO effective Dec 8, remains CSO.","Shivaswamy's base salary increased to $750k while serving in dual roles.","Simard to provide consulting guidance per existing employment agreement; severance to be paid.","Board thanks Simard for 21 years; confident in Shivaswamy's leadership during interim period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122703,"accession_number":"0001171843-25-006441","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K/A","filed_at":"2025-10-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"XBiotech amends director bio: Rademaker is consultant to multiple PE firms","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Clarifies Craig Rademaker is a consultant to several Canadian private equity firms, not a single firm.","His responsibilities principally include capital markets activities.","No change to his role as director or any compensatory arrangements.","Amendment corrects prior 8-K filed June 24, 2025, for Item 5.02."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122704,"accession_number":"0001171843-25-006266","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"XBiotech enters new employment agreement with CEO John Simard; $1.25M salary, $4.53M bonus baseline","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Base salary unchanged at $1.25M; annual bonus baseline set at $4.53M for 2025, both inflation-adjusted annually.","Severance: 3 years base salary + 3 years base bonus if terminated without cause, disability, or retirement; 80% if for cause.","Upon retirement, CEO to consult for 18 months receiving additional base salary payments plus severance.","Agreement formalizes compensation trends over past 5 years; approved by Compensation Committee of independent directors.","Executive remains CEO and President; no change in leadership roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139392,"accession_number":"0001171843-25-005673","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"XBiotech Inc. Announces Results of Annual Meeting of Stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected five directors: John Simard (12.37M for), Thomas Kündig (12.70M), Craig Rademaker (12.50M), Tevi D. Troy (12.30M), David Soffer (12.30M).","Ratified Whitley Penn LLP as auditor with 15.21M for, 0.41M against.","Approved advisory executive compensation with 11.34M for, 1.46M against.","Approved 2025 Equity Incentive Plan with 11.95M for, 0.90M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156974,"accession_number":"0001171843-25-004066","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"XBiotech appoints Dr. Thomas Kündig and Craig Rademaker to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Thomas Kündig, Director of Dermatology at University Hospital Zurich, appointed to Board and Compensation Committee effective June 24, 2025.","Craig Rademaker, private equity leader with 25+ years in finance, appointed to Board and Audit Committee, effective same date.","Both appointments expire at the 2025 Annual General Meeting; committees now include Jan-Paul Waldin, Dr. Peter Libby, and the new members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156973,"accession_number":"0001171843-25-002067","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Director W. Thorpe McKenzie retires; XBiotech to maintain one-member audit and compensation committees","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["W. Thorpe McKenzie retired from the Board effective March 27, 2025.","Company notified NASDAQ on April 1, 2025, of the retirement and intent to fill vacancies.","Audit Committee and Compensation Committee will each operate with one member under NASDAQ exceptions.","Vacancies to be filled within the time prescribed by NASDAQ Rules 5605(c)(4) and 5605(d)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156972,"accession_number":"0001171843-25-001876","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director W. Thorpe McKenzie retires from XBiotech board effective March 27, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["McKenzie served since 2009; was on Audit, Compensation, and Nominating Committees.","Retirement not due to any dispute or disagreement with the company.","Audit Committee reduced to one member (Jan-Paul Waldin); vacancies to be filled per NASDAQ rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192284,"accession_number":"0001171843-24-007128","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"XBiotech appoints renowned immunologist Dr. Tak W. Mak to its Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Mak appointed December 24, 2024 to fill board vacancy; will serve until next annual meeting.","Dr. Mak is a professor at University of Toronto, cloned T cell receptor (1984), and identified immune checkpoint CTLA-4.","He co-founded Agios Pharmaceuticals, which developed multiple FDA-approved cancer treatments.","Audit Committee remains two independent directors (McKenzie, Waldin); vacancy to be filled per Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226522,"accession_number":"0001171843-24-003541","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"XBiotech stockholders elect five directors and ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal 1: Five directors elected; John Simard received 9,032,922.58 votes for, Jan-Paul Waldin 7,407,212.58, W. Thorpe McKenzie 8,485,018.58, Donald MacAdam 8,817,755.58, Peter Libby 9,040,330.58.","Proposal 2: Ratification of Whitley Penn LLP as independent auditor for FY 2024 passed with 11,411,235.58 votes for, 146,216 against, 63,654 abstain.","All matters voted in accordance with Board recommendations; meeting held June 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245522,"accession_number":"0001171843-24-000056","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"XBiotech enters $10M convertible loan from CEO to fund new R&D facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$10M loan from CEO John Simard at 8% simple interest, secured by real estate and cash.","Loan convertible to common stock at $4.048/share at CEO's election, subject to ownership cap.","Interest-only payments semi-annually; CEO can demand cash repayment after one year.","Funds will construct a 46,000+ sq ft R&D facility on 48-acre Austin campus; construction starts Q1 2024.","New facility supports Natrunix rheumatology program and infectious disease research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298717,"accession_number":"0001171843-23-004095","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"XBiotech annual meeting elects five directors; auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["John Simard, Jan-Paul Waldin, W. Thorpe McKenzie, Donald MacAdam, and Peter Libby re-elected as directors.","Auditor Whitley Penn LLP ratified for FY 2023 with 10,983,720 votes for, 51,402 against, 1,615 abstain.","All director nominees received majority support; abstentions and broker non-votes noted.","Meeting held June 23, 2023; all items voted in line with Board recommendations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318911,"accession_number":"0001193125-23-039510","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"XBiotech appoints Angela Hu as principal financial and accounting officer, replacing Queena Han","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Angela Hu, formerly Financial Controller, becomes principal financial and accounting officer effective February 10, 2023.","Queena Han's employment as VP Finance and HR ended February 3, 2023; she receives salary through February 15, 2023 for transition.","Hu's base salary increased to $200,000 per annum in connection with her promotion.","Hu has been with XBiotech since 2015, leading quarterly close, SEC filings, and external auditor coordination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372495,"accession_number":"0001171843-22-004610","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2022-06-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"XBiotech stockholders elect five directors and ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["John Simard re-elected with 10,345,079 for, 154,052 abstentions, 1,766,205 broker non-votes.","Jan-Paul Waldin elected with 7,064,338 for, 3,434,792.50 abstentions.","W. Thorpe McKenzie, Donald MacAdam, Peter Libby re-elected with over 9 million votes each.","Ratification of Whitley Penn LLP as auditor passed with 12,037,583 for, 77,288 against, 150,464 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372494,"accession_number":"0001171843-22-003680","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2022-05-13T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"XBiotech dismisses Ernst & Young, appoints Whitley Penn as auditor for FY 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee appointed Whitley Penn LLC as independent registered public accounting firm for fiscal year ending Dec 31, 2022.","Ernst & Young was dismissed effective May 11, 2022; its reports for FY 2020 and 2021 were unqualified.","No disagreements or reportable events occurred with Ernst & Young during the past two fiscal years.","Ernst & Young furnished a letter agreeing with the Company's disclosures, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391317,"accession_number":"0001171843-22-000711","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2022-02-02T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"XBiotech extends clinical manufacturing agreement with Janssen through December 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["XBiotech entered a Manufacturing Agreement with Janssen R&D to produce clinical product including Bermekimab.","Agreement extends manufacturing support through December 2023; revenue extends cash runway for own pipeline.","Bermekimab, a True Human monoclonal antibody, was sold to Janssen in December 2019 with transitional manufacturing.","CEO John Simard stated contract manufacturing is not core business but fits well and provides runway for up-and-coming therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428435,"accession_number":"0001171843-21-004741","cik":1626878,"company_name":"XBiotech Inc.","ticker":"XBIT","form_type":"8-K","filed_at":"2021-07-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"XBiotech declares special cash dividend of $2.50 per share ($75M total)","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Extraordinary cash dividend of approx $2.50/share, aggregate up to $75M.","Payable July 23, 2021 to stockholders of record as of July 16, 2021.","CEO cites strong balance sheet, no debt, and emerging pipeline opportunities.","Company states no guarantee of future dividends; future dividends at board discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":72260000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}